Bioicus Why β-lactones are hard to make
β-Lactones are pharmacologically active because of a structural tension built into the four-membered ring. That tension is precisely what makes them useful: when the ring encounters the active site of a target enzyme, it opens irreversibly, bonding permanently to the catalytic residue and disabling the enzyme. Orlistat, the only FDA-approved β-lactone drug, works exactly this way, permanently blocking pancreatic lipase. The same pharmacology has documented activity against serine proteases relevant to oncology, inflammation, and coagulation; against cysteine proteases relevant to parasitic infection and lysosomal storage disease; and as antibacterial agents.
Why that matters
The same reactivity that makes β-lactones potent makes them extraordinarily difficult to synthesise. The ring does not discriminate: it reacts with water, solvents, and any nucleophile present during chemical synthesis, breaking apart before the final molecule is complete. Building β-lactone pharmacophores at scale has remained a persistent bottleneck in drug-discovery programmes.
Enzymatic synthesis offers a route around that problem. A biosynthetic enzyme can close the ring under controlled biological conditions, shielding the product from unwanted reactions until synthesis is complete. BIQS001 encodes the machinery to do exactly this. The resulting β-lactone compounds are expected to present different molecular geometry from known pharmacophores: different geometry means different target selectivity, and a potential new scaffold for inhibitor programmes that existing β-lactone compounds cannot reach.
What it is
BIQS001 is a β-lactone biosynthetic gene cluster identified in silico in the genome of an extremophile from the Atacama Desert, northern Chile. The cluster encodes three novel core biosynthetic enzymes: an acyl carrier protein, a ring-closing cyclase, and an adenylate-forming enzyme. Together, they constitute a previously undescribed biosynthetic route to β-lactone compounds. Discovered computationally, produced by nature.
Development status
Licensing Domains
From a microbe to a biocatalyst — each domain is available for independent licensing.
Isolated cyclase as tool enzyme.
The isolated cyclase as a standalone tool enzyme. Enables access to β-lactone chemistry without requiring expression of the full biosynthetic pathway. Suitable for academic and commercial drug-discovery laboratories exploring serine hydrolase inhibition.
Custom β-lactone libraries for screening programmes.
Chemoenzymatic synthesis of custom β-lactone compound libraries for high-throughput screening. Addresses the synthesis bottleneck that limits access to β-lactone pharmacophores in programmes targeting oncology, inflammation, and coagulation.
Scalable enzymatic β-lactone synthesis routes.
Scalable enzymatic routes to β-lactone compounds for industrial applications beyond pharma. Scope defined with the licensee based on validated pathway performance and production requirements.